GSK plc Announces Provisional 2025 Dividend Dates
Ticker: GLAXF · Form: 6-K · Filed: Nov 12, 2024 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Nov 12, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: dividend, provisional dates, regulatory filing
TL;DR
GSK dropped its 2025 dividend dates, but they're just provisional, so watch out for changes.
AI Summary
GSK plc announced its provisional dividend dates for 2025 on November 12, 2024. The announcement details the results announcement dates and ex-dividend dates for ordinary shares throughout the year, though these dates are subject to change.
Why It Matters
This filing provides investors with advance notice of GSK's planned dividend schedule for the upcoming year, aiding in their financial planning and investment decisions.
Risk Assessment
Risk Level: low — The filing is a routine announcement of provisional dividend dates and does not contain significant new financial information or strategic shifts.
Key Players & Entities
- GSK plc (company) — Registrant
- November 12, 2024 (date) — Filing date
- 2025 (date) — Dividend year
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K filing is to report GSK plc's provisional dividend dates for the year 2025.
When were the provisional 2025 dividend dates announced?
The provisional 2025 dividend dates were announced on November 12, 2024.
Are the announced 2025 dividend dates final?
No, the announcement explicitly states that these dates are indicative and may be subject to change.
What information is provided regarding the dividends?
The filing provides the results announcement dates and ex-dividend dates for GSK's ordinary shares for 2025.
What is GSK plc's principal executive office address?
GSK plc's principal executive office is located at 79 New Oxford Street, London, WC1A 1DG.
Filing Stats: 362 words · 1 min read · ~1 pages · Grade level 18.7 · Accepted 2024-11-12 06:31:55
Filing Documents
- a7602l.htm (6-K) — 29KB
- 0001654954-24-014068.txt ( ) — 30KB
SIGNATURES
SIGNATURES     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.   GSK plc   (Registrant)     Date: November 11, 2024         By:/s/ VICTORIA WHYTE --------------------------       Victoria Whyte   Authorised Signatory for and on   behalf of GSK plc